Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Journal of Cancer Research and Clinical Oncology|January 21, 2014
Dichloroacetate should be considered with platinum-based chemotherapy in hypoxic tumors rather than as a single agent in advanced non-small cell lung cancerEdward B Garon, Heather R Christofk, Wylie Hosmer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 5, 2017
Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib StudyAndrea B Apolo, Jeffrey R Infante, Ani Balmanoukian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 16, 2014
A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumorsPhilippe L Bedard, Josep Tabernero, Filip Janku, et al.
British Journal of Clinical Pharmacology|August 1, 2020
The effect of sonidegib (LDE225) on the pharmacokinetics of bupropion and warfarin in patients with advanced solid tumoursDarcy B Pooler, Dylan B Ness, John Sarantopoulos, et al.
The Lancet. Oncology|December 9, 2017
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trialManish R Patel, John Ellerton, Jeffrey R Infante, et al.
Journal of Hematology & Oncology|April 9, 2017
Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancerShikhar Mehrotra, Carolyn D Britten, Steve Chin, et al.
Cytotherapy|February 27, 2022
Need for aligning the definition and reporting of cytokine release syndrome (CRS) in immuno-oncology clinical trialsMark D Stewart, Bruce McCall, Marcelo Pasquini, et al.
Cancer Chemotherapy and Pharmacology|June 9, 2018
Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancerJordi Rodon, Alejandro Pérez-Fidalgo, Ian E Krop, et al.
Pageof 4